WEX Stock Analysis: Wex | NYSE
Software - Infrastructure | NYSE, USA | Market Cap: 5.668m USD | 12M Return: 3.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 108M
EPS Trend: 91.8%
Qual. Beats: 1
Rev. Trend: 82.6%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
WEX Inc. is a U.S.-headquartered commerce platform operator with three core business segments. The Mobility segment provides fleet payment solutions, transaction processing, and information management services for businesses and government agencies with commercial vehicle fleets, distributed through direct, indirect, co-branded, and private label channels. The Corporate Payments segment offers embedded payments, accounts payable automation, and spend management solutions to customers in travel, fintech, insurance, consumer bill pay, and media verticals. The Benefits segment delivers a SaaS platform for consumer-directed healthcare benefits, including HSA custodial services, COBRA administration, and benefit enrollment solutions marketed through third-party administrators, financial institutions, payroll providers, and health plans.
The company is classified within the GICS Industrials sector, specifically the Data Processing & Outsourced Services sub-industry, reflecting its orientation toward payment processing and software-based services rather than pure financial intermediation. Founded in 1983 and headquartered in Portland, Maine, WEX was originally known as Wright Express Corporation before rebranding in October 2012, and has been publicly traded on the NYSE since its 2005 IPO.
- Mobility fuel volume exposed to commodity prices and EV transition
- Corporate Payments growth driven by B2B embedded and travel verticals
- Benefits segment scales on consumer-directed healthcare and HSA adoption
| Net Income: 350.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.18 > 1.0 |
| NWC/Revenue: 18.03% < 20% (prev 15.38%; Δ 2.65% < -1%) |
| CFO/TA 0.02 > 3% & CFO 262.9m > Net Income 350.8m |
| Net Debt (-662.4m) to EBITDA (956.8m): -0.69 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.9m) vs 12m ago 1.45% < -2% |
| Gross Margin: 56.71% > 18% (prev 59.60%; Δ -2.89% > 0.5%) |
| Asset Turnover: 17.91% > 50% (prev 17.71%; Δ 0.21% > 0%) |
| Interest Coverage Ratio: 3.13 > 6 (EBIT TTM 714.9m / Interest Expense TTM 228.4m) |
| A: 0.03 (Total Current Assets 11.8b - Total Current Liabilities 11.3b) / Total Assets 16.5b |
| B: 0.15 (Retained Earnings 2.56b / Total Assets 16.5b) |
| C: 0.05 (EBIT TTM 714.9m / Avg Total Assets 15.6b) |
| D: 0.09 (Book Value of Equity 1.34b / Total Liabilities 15.2b) |
| Altman-Z'' = 1.11 = BB |
| DSRI: 1.13 (Receivables 4.76b/3.92b, Revenue 2.79b/2.60b) |
| GMI: 1.05 (GM 59.60% / 56.71%) |
| AQI: 0.87 (AQ_t 0.27 / AQ_t-1 0.31) |
| SGI: 1.07 (Revenue 2.79b / 2.60b) |
| TATA: 0.01 (NI 350.8m - CFO 262.9m) / TA 16.5b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of July 29, 2026, the stock is trading at USD 182.88 with a total of 1,548,108 shares traded. Over the past week, the price has changed by +13.62%, over one month by +33.75%, over three months by +19.95% and over the past year by +3.94%.
Current recommended Stop Loss: 173.80 (which is 5% or 1.3 ATR below the current price).
Wex has received a consensus analysts rating of 3.31. Therefore, it is recommended to hold WEX.
- StrongBuy: 2
- Buy: 1
- Hold: 13
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 178.2 | -2.6% |
P/E Trailing = 17.5507
P/E Forward = 7.874
P/S = 2.008
P/B = 4.235
P/EG = 0.875
Revenue TTM = 2.79b USD
EBIT TTM = 714.9m USD
EBITDA TTM = 956.8m USD
Long Term Debt = 3.53b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.83b USD (from shortTermDebt, last quarter)
Debt = 5.44b USD (from shortLongTermDebtTotal, last quarter) + Leases 82.0m
Net Debt = -662.4m USD (calculated: Debt 5.44b - CCE 6.10b)
Enterprise Value = 5.01b USD (5.67b + Debt 5.44b - CCE 6.10b)
Interest Coverage Ratio = 3.13 (Ebit TTM 714.9m / Interest Expense TTM 228.4m)
EV/FCF = 46.13x (Enterprise Value 5.01b / FCF TTM 108.5m)
FCF Yield = 2.17% (FCF TTM 108.5m / Enterprise Value 5.01b)
FCF Margin = 3.89% (FCF TTM 108.5m / Revenue TTM 2.79b)
Net Margin = 12.56% (Net Income TTM 350.8m / Revenue TTM 2.79b)
Gross Margin = 56.71% ((Revenue TTM 2.79b - Cost of Revenue TTM 1.21b) / Revenue TTM)
Gross Margin QoQ = 55.77% (prev 56.29%)
Tobins Q-Ratio = 0.30 (Enterprise Value 5.01b / Total Assets 16.5b)
Interest Expense / Debt = 4.20% (Interest Expense 228.4m / Debt 5.44b)
Taxrate = 27.75% (134.7m / 485.4m)
NOPAT = 516.5m (EBIT 714.9m * (1 - 27.75%))
Current Ratio = 1.04 (Total Current Assets 11.8b / Total Current Liabilities 11.3b)
Debt / Equity = 4.05 (Debt 5.44b / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = -0.69 (Net Debt -662.4m / EBITDA 956.8m)
Debt / FCF = -6.10 (Net Debt -662.4m / FCF TTM 108.5m)
Total Stockholder Equity = 1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.25% (Net Income 350.8m / Total Assets 16.5b)
RoE = 28.22% (Net Income TTM 350.8m / Total Stockholder Equity 1.24b)
RoCE = 14.97% (EBIT 714.9m / Capital Employed (Equity 1.24b + L.T.Debt 3.53b))
RoIC = 7.50% (NOPAT 516.5m / Invested Capital 6.89b)
WACC = 6.73% (E(5.67b)/V(11.1b) * Re(10.28%) + D(5.44b)/V(11.1b) * Rd(4.20%) * (1-Tc(0.28)))
Discount Rate = 10.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -90.90 | Cagr: -7.80%
[DCF] Terminal Value 73.10% ; FCFF base≈172.8m ; Y1≈151.6m ; Y5≈122.4m
[DCF] Fair Price = 75.80 (EV 1.97b - Net Debt -662.4m = Equity 2.63b / Shares 34.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 91.77 | EPS CAGR: 5.45% | SUE: 0.96 | # QB: 1
Revenue Correlation: 82.62 | Revenue CAGR: 2.56% | SUE: 1.28 | # QB: 1
EPS current Quarter (2026-09-30): EPS=5.45 | Chg30d=+0.47% | Revisions=+25% | Analysts=13
EPS current Year (2026-12-31): EPS=19.39 | Chg30d=+0.42% | Revisions=+40% | GrowthEPS=+20.4% | GrowthRev=+7.4%
EPS next Year (2027-12-31): EPS=20.43 | Chg30d=+0.63% | Revisions=-17% | GrowthEPS=+5.4% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: +22% (up=4, down=2)